Patient Preferences in Psoriasis Treatments: A Study Overview

Introduction to Topical Therapies

A recent investigation published in the Journal of the European Academy of Dermatology and Venereology explored patient preferences between gel and foam formulations of topical therapies for psoriasis. Treatment plans for psoriasis typically include topical options such as creams, lotions, foams, ointments, or gels. These therapies can serve as the primary approach for mild-to-moderate cases or complement ultraviolet or systemic therapies for more severe manifestations.

Challenges with Treatment Adherence

Despite the potential benefits of topical treatments, adherence remains a significant challenge, with some studies indicating rates as low as 40%. Factors contributing to poor adherence vary, encompassing practical issues like lengthy application times and cosmetic concerns regarding the appearance of the products.

Safety and Efficacy of Calcipotriol and Betamethasone

Prior research has validated the safety and effectiveness of a fixed combination of calcipotriol (Cal) and betamethasone dipropionate (BD). Both ointment and gel forms of this combination are commonly prescribed, but to enhance adherence and offer patients more choices, an aerosol foam formulation was developed, which has been positively received.

The PSO-INSIGHTFUL Study

To delve deeper into the reasons behind poor adherence, the recent study compared Cal/BD foam to its gel version, considering the last topical treatment each patient received. The PSO-INSIGHTFUL study involved multiple centers recruiting adult patients from Canada and Germany suffering from mild-to-severe psoriasis. After a washout period of up to four weeks without any topical medications, patients were randomized to use either Cal/BD foam or gel for one week each.

Study Findings and Patient Experiences

Of the 213 patients randomized, 118 had received treatment within the last three months. They completed six questionnaires assessing their experiences with both products. Results indicated that patient preferences were generally similar for both Cal/BD foam and gel, with both formulations receiving high scores for usability and satisfaction. This suggests that preferences for topical therapies extend beyond mere efficacy.

Key Characteristics Influencing Preferences

The study identified several critical characteristics that influence patient preference for topical therapies, including texture, ease of application, and packaging. Notably, both the foam and gel were favored over the last topical treatment patients had used, particularly when compared to ointments or creams, likely due to the greasiness and messiness associated with those options.

Specific Preferences Based on Psoriasis Severity

Interestingly, the results revealed that patients with more extensive psoriasis favored Cal/BD gel, while those with localized psoriasis preferred the foam. This distinction suggests that Cal/BD gel may be better suited for patients with widespread psoriasis, whereas the foam may be ideal for those with larger, localized lesions.

Individualized Treatment Approaches

The researchers emphasize that there is no universal solution for treating psoriasis. Considering the diverse preferences and needs of patients is vital for medical providers when selecting the appropriate formulation. This individualized approach is expected to enhance treatment adherence and, ultimately, improve patient outcomes and quality of life.

Conclusion

In summary, the PSO-INSIGHTFUL study highlights the importance of understanding patient preferences in topical therapies for psoriasis. By tailoring treatment plans to individual needs, healthcare providers can foster better adherence and enhance the overall efficacy of psoriasis management.

References

Hong, C. H., Papp, K. A., Lophaven, K. W., Skallerup, P., & Philipp, S. (2017). Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: Randomized Phase IIIb PSO‐INSIGHTFUL study. Journal of the European Academy of Dermatology and Venereology.